Market
Daiichi Sankyo stock rises 10%+ within one week of FDA decision on avutometinib plus defactinib?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Stock market data from financial platforms like Bloomberg or Yahoo Finance
Story
FDA Grants Priority Review for KRAS-Mutant Ovarian Cancer Drug; DATROWAY Approved, Daiichi Sankyo Stock Rises 8%
Jan 20, 2025, 05:20 AM
The U.S. Food and Drug Administration (FDA) has accepted and granted priority review for the new drug application (NDA) of avutometinib plus defactinib, aimed at treating patients with recurrent low-grade serous ovarian cancer, particularly those with KRAS mutations. This follows the recent authorization of a breast cancer treatment developed by AstraZeneca and Daiichi Sankyo, which marks the first U.S. approval for this closely watched therapy. The drug, known as DATROWAY, has been approved for patients with previously treated metastatic hormone receptor-positive, HER2-negative breast cancer. Following this approval, Daiichi Sankyo's stock rose over 8%, reflecting investor optimism about the drug's potential in the market.
View original story
Similar markets
Increase by 10% or more • 25%
Decrease by less than 10% • 25%
Increase by less than 10% • 25%
Decrease by 10% or more • 25%
Yes • 50%
No • 50%
Increase by 1-10% • 25%
Increase by more than 10% • 25%
Decrease • 25%
No significant change • 25%
Biogen stock falls >5% • 25%
Biogen stock stable ±5% • 25%
Other • 25%
Biogen stock rises >5% • 25%
Performs in line with biotech index • 25%
No significant change • 25%
Underperforms biotech index • 25%
Outperforms biotech index • 25%
Increase by more than 10% • 25%
No increase or decrease • 25%
Increase less than 5% • 25%
Increase by 5-10% • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Decrease • 25%
Increase 0-20% • 25%
Increase over 20% • 25%
No change • 25%
Decrease • 25%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
No significant change • 25%